Over 27 million American adults took melatonin in the past year, making it the top-selling sleep supplement in the United States by a wide margin. Sales have tripled since 2017, driven by pandemic-era sleep disruption and a cultural shift toward supplement-based self-medication. Yet melatonin may be the most misunderstood supplement on the market. Dr. Richard Wurtman, professor of neuroscience at MIT and the researcher who first identified melatonin's role as a chronobiotic signal in the 1990s, has spent three decades arguing that most consumers are taking too much, too late, and for the wrong indication. Understanding what melatonin actually is — and what it is not — reframes its proper use entirely.
Melatonin Is Not a Sleeping Pill
Melatonin is a hormone produced by the pineal gland in response to darkness. Its primary function is not to induce sleep but to signal to the brain that it is nighttime — a chronobiotic signal that synchronizes the circadian clock. The distinction matters clinically: melatonin is most effective for conditions involving circadian misalignment (jet lag, shift work, delayed sleep-wake phase disorder) and substantially less effective for general insomnia, where the circadian clock is properly set but other factors — anxiety, pain, hyperarousal, medical conditions — are preventing sleep.
A PLoS ONE meta-analysis (k=19 trials, n=1,683, led by Dr. Eduardo Ferracioli-Oda at Yale University) quantified the difference: melatonin reduces sleep onset latency by an average of 7.06 minutes in primary insomnia — a statistically significant but clinically modest effect. In contrast, for delayed sleep-wake phase disorder — where the circadian clock is shifted late, making people unable to fall asleep until 2–4 a.m. — melatonin reduces onset latency by 22–34 minutes and shifts the circadian phase forward by 1–2 hours. The effect is substantial when the mechanism matches the indication and marginal when it does not.
Dr. Charles Czeisler, professor of sleep medicine at Harvard Medical School and chief of the Division of Sleep and Circadian Disorders at Brigham and Women's Hospital, has emphasized this distinction: "Giving melatonin for insomnia is like taking an antibiotic for a virus. It is the wrong tool for the wrong problem. Melatonin tells the brain what time it is. It does not knock the brain out."
The Dosing Problem: Why More Is Not Better
Dr. Alfred Lewy, a psychiatrist at Oregon Health and Science University who pioneered clinical melatonin research in the 1980s, demonstrated that the dose-response curve for melatonin is not linear — it is an inverted U. Low doses (0.3–0.5 mg) produce plasma levels that mimic the natural nocturnal peak and effectively shift the circadian clock. Higher doses (3–10 mg) flood melatonin receptors (MT1 and MT2), producing supraphysiological blood levels that persist into the morning, cause grogginess, and may downregulate receptor sensitivity over time — meaning the supplement becomes less effective with continued use.
Why do supplement companies sell 3, 5, and 10 mg tablets? Because melatonin is regulated as a dietary supplement in the United States, not as a pharmaceutical. There is no FDA review of optimal dosing, and supplement manufacturers have a commercial incentive to offer higher doses — consumers interpret "more milligrams" as "more effective," a perception that is factually wrong for melatonin but profitable for manufacturers.
The practical recommendation from every leading melatonin researcher is consistent: start at 0.3–0.5 mg. If you cannot find tablets that low, purchase a 1 mg tablet and cut it in half. Increasing the dose will not make melatonin work better; it will make it work differently — producing sedation through receptor flooding rather than circadian alignment, with diminishing returns and more side effects.
Timing Matters More Than Dose
Take melatonin 1–2 hours before your desired bedtime, not at bedtime. The purpose is to advance the circadian phase — to tell the brain that darkness has arrived and sleep should begin soon. Taking it at the moment you want to fall asleep is too late for the chronobiotic effect; the circadian signal needs time to propagate.
For jet lag, the protocol depends on direction of travel. Eastward travel (advancing the clock): take melatonin at the destination's bedtime, starting the evening of travel and continuing for 3–5 nights after arrival. Westward travel (delaying the clock): melatonin is less useful; morning bright light exposure is more effective. For shift workers, Dr. Charmane Eastman, professor of behavioral sciences at Rush University Medical Center, has published protocols showing that timed melatonin combined with scheduled bright light exposure can shift the circadian phase by 2–3 hours per day — enough to adapt to a new shift schedule within 3–4 days rather than the 7–10 days of unaided adjustment.
Light exposure is melatonin's counterpart and competitor. Bright light (especially blue-enriched light above 480 nm) suppresses melatonin production via the retinohypothalamic tract to the suprachiasmatic nucleus. Scrolling your phone in bed after taking melatonin partially defeats the purpose — the exogenous melatonin says "it's dark," while the screen light says "it's daytime." Reducing bright light exposure in the 2 hours before bed amplifies melatonin's effectiveness whether or not you take a supplement.
Quality Concerns: What Is Actually in the Bottle
A 2017 study by Dr. Lauren Erland and Dr. Praveen Saxena at the University of Guelph, published in the Journal of Clinical Sleep Medicine, tested 31 commercially available melatonin supplements and found alarming variability: actual melatonin content ranged from 83% less to 478% more than what the label stated. A 1 mg tablet might contain 0.17 mg or 5.78 mg — a 34-fold range within the same "dose." Even more concerning, 26% of the products contained serotonin as a contaminant — a neurotransmitter that should not be present in any supplement and can cause adverse effects at sufficient doses.
This quality variability is a direct consequence of the supplement industry's regulatory structure: the FDA does not require pre-market testing of supplements for purity, potency, or accuracy of labeling. Manufacturers are responsible for their own quality control, and enforcement actions are rare. For consumers, the practical solution is to purchase melatonin with third-party certification from NSF International, USP (United States Pharmacopeia), or ConsumerLab — organizations that independently verify that the product contains what the label claims, free of contaminants.
Melatonin in Children: Proceed with Caution
Melatonin use in children has increased dramatically — a 2022 CDC report noted a 530% increase in pediatric melatonin use from 2012 to 2021, along with a sharp rise in pediatric poison control calls (primarily accidental ingestion of gummy melatonin products). Dr. Judith Owens, professor of neurology at Harvard Medical School and director of the Center for Pediatric Sleep Disorders at Boston Children's Hospital, notes that the American Academy of Pediatrics does not recommend routine melatonin use in healthy children with typical sleep difficulties.
Where melatonin has a documented clinical role in pediatrics: children with neurodevelopmental disorders — particularly autism spectrum disorder and ADHD — frequently exhibit disrupted circadian rhythms and delayed melatonin onset. A Developmental Medicine and Child Neurology systematic review (k=13 trials, n=795) confirmed efficacy in these populations, with melatonin reducing sleep onset latency by 28 minutes on average and increasing total sleep time by 33 minutes. The effects are clinically meaningful for families managing severe bedtime resistance and sleep deprivation.
The unresolved concern: melatonin's long-term effects on pubertal development in children remain unstudied. Melatonin interacts with the hypothalamic-pituitary-gonadal axis, and animal studies suggest it can influence the timing of puberty. No human study has tracked melatonin-supplemented children through puberty. Dr. Owens has emphasized that this is not evidence of harm — it is an absence of evidence of safety, which is a different and important distinction for parents making supplementation decisions.
Extended-Release vs. Immediate-Release
Standard (immediate-release) melatonin has a very short half-life: 20–40 minutes. It produces a sharp spike in plasma melatonin that signals sleep onset but dissipates quickly — usually within 90 minutes. This profile is ideal for people who have difficulty falling asleep but stay asleep once they do.
For individuals who fall asleep easily but wake at 2–3 a.m. and cannot return to sleep, the problem is not sleep onset but sleep maintenance — and immediate-release melatonin at any dose does not address it. Extended-release formulations (also called sustained-release or controlled-release) deliver melatonin over 6–8 hours, mimicking the natural overnight production curve. A 2014 Neurology trial (n=240, led by Dr. Nir Giladi at Tel Aviv University) found that extended-release melatonin at 2 mg improved sleep quality in patients over 55 without next-day impairment — one of the few studies supporting a higher dose in a specific population (older adults, who produce less endogenous melatonin).
The Bottom Line
Melatonin works — for the right indication, at the right dose, at the right time. It is a chronobiotic, not a sedative. It is most effective for circadian misalignment and least effective for general insomnia. The optimal dose is 0.3–0.5 mg, taken 1–2 hours before desired bedtime. Higher doses produce more side effects without more benefit. Quality varies wildly between brands; third-party certification is essential. For children, it should be reserved for neurodevelopmental conditions under clinical guidance. For everyone, reducing evening light exposure enhances melatonin's effect — whether endogenous or supplemental — more reliably than increasing the dose.